Meeting
2016 Genitourinary Cancers Symposium
Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure.
Authors
Jeffrey Karnes
Mayo Clinic, Rochester, MN
Jeffrey Karnes , Hussam Al-Deen Ashab , Bruce J. Trock , Ashley Ross , Harrison Tsai , Jeffrey J. Tosoian , Nicholas Erho , Voleak Choeurng , Kasra Yousefi , Zaid Haddad , Firas Abdollah , Eric A. Klein , Paul L. Nguyen , Felix Yi-Chung Feng , Adam Dicker , Robert Benjamin Den , Elai Davicioni , Robert B. Jenkins , Tamara L. Lotan , Edward M. Schaeffer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 106)
DOI
10.1200/jco.2016.34.2_suppl.106
Abstract #
106
Poster Bd #
E22
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Development and validation of genomic signature to predict ADT treatment failure.
First Author: Jeffrey Karnes
Poster
2023 ASCO Genitourinary Cancers Symposium
Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.
First Author: Adam B Weiner
Poster
2023 ASCO Genitourinary Cancers Symposium
Cardiovascular and thromboembolic events associated with intense neoadjuvant androgen deprivation therapy followed by prostatectomy in patients with localized prostate cancer: A meta-analysis of clinical trials.
First Author: Eduardo Felicio Campos
Poster
2023 ASCO Genitourinary Cancers Symposium
Evaluating p53 nuclear expression and prostate cancer progression in a predominantly African American cohort.
First Author: William Gesztes